<DOC>
	<DOC>NCT00886821</DOC>
	<brief_summary>The purpose of this study is to determine safety and tolerability of CVX-096 in adult, type 2 diabetic patients.</brief_summary>
	<brief_title>A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Male and/or female patients (females will be women of nonchildbearing potential) with an historical diagnosis of type 2 diabetes mellitus, who are currently being treated with metformin at a dose at or near maximum. Hb A1c between 710%. Fasting Cpeptide &gt;0.4 nmol/L. History of clinically significant chronic conditions other than T2DM not well controlled by either diet or medications. Patients with pancreatitis or considered a high risk for pancreatitis. History of contraindications to metformin therapy. Previous treatment with an approved or investigational GLP 1 mimetic.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Phase 1 Type 2 diabetes CVX-096 diabetes mellitus</keyword>
	<keyword>adult-onset diabetes mellitus</keyword>
	<keyword>non-insulin dependent</keyword>
</DOC>